Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 77,587 Shares of Company Stock

Key Points

• Insider John Paolini sold 77,587 Kiniksa shares for about $7.22 million, reducing his stake by 52.6% to 69,922 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
• Kiniksa’s latest quarterly results beat expectations, reporting EPS of $0.56 versus $0.37 expected and revenue of $285.97 million versus $260.66 million expected.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $100.57; shares recently traded near $93.29.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider John Paolini sold 77,587 shares of the stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $93.02, for a total transaction of $7,217,142.74. Following the completion of the transaction, the insider directly owned 69,922 shares of the company's stock, valued at $6,504,144.44. This trade represents a 52.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA traded up $2.49 during midday trading on Tuesday, reaching $93.29. 1,021,631 shares of the company traded hands, compared to its average volume of 705,858. The firm has a market cap of $7.28 billion, a PE ratio of 71.76 and a beta of 0.04. The stock's 50-day simple moving average is $79.39 and its 200-day simple moving average is $60.29. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. The business had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on KNSA. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a research report on Wednesday, October 28th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 12th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 28th. Finally, Citigroup upped their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and an average target price of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ethic Inc. bought a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $726,000. Pictet Asset Management Holding SA lifted its stake in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company's stock valued at $64,182,000 after acquiring an additional 251,578 shares during the period. AlphaCentric Advisors LLC bought a new position in Kiniksa Pharmaceuticals International in the third quarter valued at about $596,000. Commonwealth Equity Services LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company's stock valued at $811,000 after acquiring an additional 237 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in Kiniksa Pharmaceuticals International in the third quarter worth about $226,000. 53.95% of the stock is owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.